# Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690

> **NCT04046250** · PHASE2 · COMPLETED · sponsor: **Tosk, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Mucositis

## Interventions

- **DRUG:** TK-112690
- **DRUG:** Placebo TK-112690

## Key facts

- **NCT ID:** NCT04046250
- **Lead sponsor:** Tosk, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-15
- **Primary completion:** 2019-10-10
- **Final completion:** 2020-03-31
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04046250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04046250, "Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04046250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*